A Phase 2a, Multi-Center, Open-Label Study of I-131-CLR1404 in Subjects With Recurrent Glioma.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 21 Apr 2014
At a glance
- Drugs CLR 1404 I-131 (Primary)
- Indications Glioma
- Focus Therapeutic Use
- Sponsors Cellectar Biosciences
- 19 Feb 2014 Status changed from not yet recruiting to withdrawn prior to recruitment, as per ClinicalTrials.gov record.
- 09 Jul 2013 Planned initiation date changed from 1 May 2013 to 1 May 2014 as reported by ClinicalTrials.gov record.
- 09 Jul 2013 Status changed from planning to not yet recruiting as reported by ClinicalTrials.gov record.